![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Similar Declines in HIV-1 RNA (Viral load, VL) from
Baseline (BL) to 96 Weeks Observed in Subjects
Randomized to ABC/3TC or TDF/FTC each with
Lopinavir/Ritonavir (LPV/r) in the HEAT Trial (EPZ104057)
|
|
|
Reported by Jules Levin
5th IAS Capetown July 19-22 2009
Linda Yau1, Jaime Hernandez2, Parul Patel1, Lynn Dix1, Keith Pappa1, and Mark Shaefer1
1GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, USA; 2BioCryst Pharmaceuticals, Inc., Cary, North Carolina, USA.
![image002.gif](../images/080409/080409-3/image002.gif)
![image004.gif](../images/080409/080409-3/image004.gif)
![image006.gif](../images/080409/080409-3/image006.gif)
![image008.gif](../images/080409/080409-3/image008.gif)
![image010.gif](../images/080409/080409-3/image010.gif)
![image012.gif](../images/080409/080409-3/image012.gif)
![image014.gif](../images/080409/080409-3/image014.gif)
![image016.gif](../images/080409/080409-3/image016.gif)
![image018.gif](../images/080409/080409-3/image018.gif)
![image020.gif](../images/080409/080409-3/image020.gif)
![image022.gif](../images/080409/080409-3/image022.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|